| 姚程飞,沈晓燕,徐敏敏.可溶性纤维介素蛋白2(sFGL2)在肝细胞肝癌患者术后早期复发中的预测价值[J].浙江中西医结合杂志,2020,30(8): |
| 可溶性纤维介素蛋白2(sFGL2)在肝细胞肝癌患者术后早期复发中的预测价值 |
| Clinical utility of soluble fibrinogen-like protein 2 in predicting recurrence of patients with hepatocellular carcinoma |
| 投稿时间：2019-03-14 修订日期：2020-06-29 |
| DOI： |
| 中文关键词: 肝细胞肝癌 可溶性纤维介素蛋白2 复发 |
| 英文关键词:hepatocellular carcinoma soluble fibrinogen-like protein 2 recurrence |
| 基金项目: |
|
| 摘要点击次数: 956 |
| 全文下载次数: 9 |
| 中文摘要: |
| 目的:研究可溶性纤维介素蛋白2(soluble fibrinogen-like protein 2, sFGL2)在评估和预测肝细胞肝癌患者切除术后复发中的临床意义。方法: 在绍兴第二医院肝细胞肝癌切除术患者111例。通过Fisher确切概率法和COX回归分析法评估术前sFGL2水平在肝细胞肝癌患者切除术后复发中的临床价值。结果: 111名肝细胞肝癌患者其中位随访时间为30.3个月,期间共有47例肝细胞肝癌患者发生复发,同时复发组肝细胞肝癌患者的sFGL2水平显著高于未复发组肝细胞肝癌患者sFGL2水平。根据sFGL2的平均值62.89ng/mL作为决定值,将肝细胞肝癌患者人群分为高sFGL2组和低sFGL2组。多因素分析显示sFGL2是预测肝癌术后复发的独立危险因子(OR：1.90；95%CI：1.01-3.53；P=0.045)。sFGL2水平与肝癌患者的临床病理特征具有显著的相关性(P<0.05)。结论: sFGL2是一个简便、高效、易检测、低成本的肝细胞肝癌患者切除术后复发预测指标,sFGL2 > 62.89ng/mL的肝细胞肝癌患者术后复发风险显著增加,sFGL2有利于肝细胞肝癌综合治疗监测。 |
| 英文摘要: |
| Objective: The study was designed to investigate and assess the clinical utility of soluble fibrinogen-like protein 2 (sFGL2) in predicting recurrence risk of hepatocellular carcinoma (HCC) patients after curative resection. Methods: The clinical data of 111 HCC patients undergoing curative resection were collected. Difference of recurrence rates between these two groups in entire cohort were compared via Kaplan-Meier curves and log-rank tests. Univariate and multivariate analysis were performed to determine the independent factor for predicting tumor recurrence. Results: The median follow-up time was 30.3 months, and 47 patients encountered recurrence during this period. HCC patients were stratified into two groups based on the average value of sFGL2. Multivariate analysis revealed that sFGL2 was the independent indictor for predicting recurrence. Conclusion: sFGL2 was a convenient, powerful, easy-obtained, and low-cost prognostic indicator of recurrence prediction after curative resection. HCC patients with sFGL2 > 62.89 ng/mL had more risk of encountering recurrence. In clinical practice, detection of sFGL2 can help making more effective systematic HCC treatment strategy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
